Improved survival in HIV-infected persons
Gary Stein
Journal of Antimicrobial Chemotherapy July 2007 60(3):461-463;
doi:10.1093/jac/dkm241
Nicolai Lohse1,2,*, Ann-Brit Eg Hansen3,4, Jan Gerstoft4 and Niels Obel4
1 Department of Clinical Epidemiology, Århus University Hospital, DK-8000
Århus C, Denmark 2 The Danish HIV Cohort Study, Copenhagen University
Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark 3 Department of
Infectious Diseases, Odense University Hospital and Clinical Institute,
University of Southern Denmark, DK-5000 Odense, Denmark 4 Department of
Infectious Diseases, Copenhagen University Hospital Rigshospitalet, DK-2100
Copenhagen, Denmark
Conclusion
Many HIV-infected persons with access to antiretroviral therapy have a
near-normal life expectancy, but mortality among them is still higher than
that in the general population. The continuation of the positive trend may
be achieved by vaccine development, increased HIV testing, earlier HAART
initiation, individually tailored regimens, improved drug adherence,
prevention and treatment of HIV-unrelated co-morbidity and collaboration
with other medical specialists to treat an ageing co-morbidity-acquiring HIV
population.
Abstract
A human immunodeficiency virus (HIV) patient in 2007 has the option to
commence an antiretroviral regimen that is extremely efficacious in
suppressing the virus and has few side effects. In a recent study, we
estimated the median remaining lifetime of a newly diagnosed 25-year-old
HIV-infected individual to be 39 years. The prospect of a near-normal life
expectancy has implications for the HIV-infected persons as well as for the
handling of the disease in the healthcare system. The patients can now on a
long-term perspective plan their professional career, join a pension plan
and start a family. Further, they may expect to be treated equally with
other members of society with respect to access to mortgage, health
insurance and life insurance. As the infected population ages, more patients
will contract age-related diseases, and the disease burden on some
individuals may even come to be dominated by non-HIV-related conditions that
may have a worse prognosis and therefore become more important than
HIV-related conditions. Despite the improvements in antiretroviral therapy,
there is still an excess mortality among HIV patients, which appears to be
only partially attributable to immunodeficiency, with lifestyle factors
potentially playing a pronounced role. Consequently, an effort to further
increase survival must target risk factors for both HIV-related
and -unrelated mortality. The continuation of the positive trend may be
achieved by increased HIV testing, earlier initiation of antiretroviral
therapy, improved drug adherence, prevention and treatment of HIV-unrelated
co-morbidity and collaboration with other medical specialists to treat an
ageing co-morbidity-acquiring HIV population.
Background
The effectiveness of highly active antiretroviral therapy (HAART) against
the human immunodeficiency virus (HIV) has been a medical success story. For
those fortunate enough to have access to HAART, an inevitably deadly disease
has turned into a chronic condition. In the 1980s, simply finding a drug or
drug combination that could delay AIDS or death was the main clinical goal.
In the mid-1990s, triple-combination therapy was introduced, leading to
substantially prolonged survival. Simultaneously, it was shown that the
substrate for the clinical effectiveness was suppression of HIV
replication.1 Many patients experienced the comfort of a rising CD4 cell
count and reversal of their AIDS-defining conditions. However, short-term
and long-term side effects of the drugs became increasingly concerning,
whereas episodes of virological failure led to the development of drug
resistance, forcing patients to resort to often less efficacious second- or
third-line regimens. Pharmaceutical companies began competing to develop new
drugs with fewer side effects, lower pill burden and a better tolerance to
non-compliance. Patients and physicians speculated whether controlled
treatment interruptions could bring about a clinical success by delaying the
potential exhaustion of available drug combinations and reducing the harm
due to side effects. The intensive drug development and the massive research
into mechanisms of resistance and side effects have paid off. An HIV patient
in 2007 has the option to commence a drug combination that is both
efficacious in suppressing the virus and has few side effects. Despite HIV's
ability to escape antiviral pressure, the rate of resistance to the
antiviral drugs-a major problem in the early years when the regimens were
suboptimal-is declining in a number of settings and may be <1% annually.
Thus, there is growing optimism among HIV experts that a large proportion of
their patients will be able to remain on their initial regimens and survive
for many years. The big question has been, though, how long?
Survival of HIV-infected persons
Our group has addressed this question in the Danish HIV Cohort Study, using
data from a population-based cohort of all HIV-infected persons in Denmark,
a country with free tax-supported medical care, including universal,
income-independent access to HAART.2 The high quality of the Danish Civil
Registration System3 enabled us to compare, with little attrition, the
survival of HIV patients with that of a matched cohort from the general
population. Life-table methods were used to estimate survival of a
25-year-old HIV-infected person, regardless of whether the person had
started HAART. The estimated median remaining lifetime has increased from 8
years in 1995-96 to 23 years in 1997-99 to 33 years in 2000-05. Among
persons not co-infected with the hepatitis C virus (HCV), the median
remaining lifetime in 2000-05 was 39 years (95% CI: 35-40 years), similar to
that of a young person with diabetes.4 In comparison, the median remaining
lifetime for a 25-year-old HIV-uninfected person was 51 years. Furthermore,
we found that neither time since diagnosis nor duration of HAART was
associated with an increased mortality. Importantly, the highest mortality
was observed in the first year after the initiation of treatment.
Immediate implications of the improved prognosis
As clinicians know, the prognosis for individual HIV patients depends on
many determinants, including immune status at the time of diagnosis,
harbouring of a drug-resistant virus strain, adherence to treatment and
concomitant infection with HCV. Nevertheless, the overall improved
prognosis, with the prospect of a near-normal life, has implications for the
HIV-infected persons as well as for their physicians. The patients may now
plan their professional career, join a pension plan, start a family-things
that just a few years ago seemed to be irrelevant luxuries. They may expect
to be treated equally with other members of society and to have easy access
to mortgage, health insurance and life insurance. They also expect to
receive high-quality healthcare for non-HIV-related conditions, including
fertility treatment. As the patients now get older, they will contract
age-related diseases, and the disease burden on some individuals may even
come to be dominated by non-HIV-related conditions. Some of these diseases
may have a worse prognosis and therefore become more important than HIV for
some patients. It would be important to know when an HIV-infected person
needs a hip replacement, a bypass operation or even a cardiac
transplantation.5 Elements of healthy lifestyle-smoking cessation, weight
loss and regular physical exercise-that take 10 years or more to yield full
benefits are becoming increasingly relevant for HIV patients. Furthermore,
they should be offered prophylactic treatments, such as cholesterol-lowering
therapy and antihypertensive treatment, just as their non-HIV-infected
counterparts do.
Why do HIV patients still have a higher risk of death?
Even though survival has increased markedly, HIV-infected persons still die
at rates that are 3-15 times higher than the general population.2
Cause-specific rates have decreased for both HIV-related and non-HIV-related
mortality, but the decreased risk of AIDS has led to a change in patterns of
co-morbidity and causes of death, and most deaths (50% to 70% of all deaths)
are now non-HIV-related.2,6-8
Common causes of non-HIV-related death are non-AIDS-defining cancers (10% of
all deaths), cardiovascular diseases (about 7%), substance abuse-related
death (about 7%), liver-related death (up to 15% reported) and bacterial
infections (about 6%).7-9 The Data Collection on Adverse Events of Anti-HIV
Drugs (DAD) study found mortality rates of non-AIDS-defining cancers to be
related to the degree of immunodeficiency. Some cancers are known to be
associated with lifestyle-related viral infections, such as hepatitis B
virus (hepatocellular carcinoma), HCV (hepatocellular carcinoma and
lymphoma) or human papilloma virus (anal, mouth and throat cancer),9 whereas
others may be associated with smoking (cancer of lung, mouth and throat).10
Liver-related deaths are mainly seen in hepatitis C or B co-infected
patients and the actual risk varies with the prevalence of these
co-infections.11 We have found that a large part of the increased mortality
seen in HIV/HCV co-infected individuals is associated with family-related
risk behaviours-mainly drug abuse-and to a lesser extent, with the HCV
infection itself.12 Behavioural risk factors for disease and death, such as
cigarette smoking and excessive alcohol consumption, are common in many
HIV-infected populations.13,14 Thus, the excess mortality among HIV patients
appears to be only partially attributable to immunodeficiency, with
lifestyle factors potentially playing a pronounced role. Consequently, an
effort to further reduce mortality and increase survival must target risk
factors for both HIV-related and HIV-unrelated mortality.
How can we provide better care for the patients?
A reduction in HIV-related mortality requires improved virological
suppression, and research has shown that adherence to therapy is the key to
success.15 The first step is easy and free access to drugs and healthcare,
which should be supplemented by a coordinated effort of experienced care
teams-physicians, nurses and social workers-in order to adequately address
each individual's needs, problems and taboos. Further, and in line with
current CDC recommendations,16 test frequency must be increased for
individuals at risk of being HIV-infected, including all adults in
healthcare settings. This may help identify HIV-infected patients at an
earlier stage of the disease and thereby enable timely therapy initiation.
Reducing non-HIV-related mortality calls for a multifaceted approach whose
success partly depends on behavioural changes that physicians can merely
encourage, but not enforce. In addition, physicians must be aware that the
HIV-infected population is getting older and therefore becomes increasingly
affected by the diseases common in the general population. Optimal treatment
and prevention therefore require the expertise of other medical specialists.
What can be done to stem the epidemic?
In order to optimize the benefit of the highly efficacious antiretroviral
drugs that are available today, we must understand how the new treatment
strategies may affect the spread of the disease on the population level. The
improved survival increases the prevalence of persons who carry HIV and are
thus at risk for transmitting the virus to others. In addition, the
awareness of improved prognosis may cause people to be less afraid of
getting infected and cause them to become less vigilant. Furthermore,
increased use of HAART may lead to resurgence of drug resistance. In
contrast, a combination of high adherence and efficacious regimens will
maintain viral suppression in the population and prevent the development of
resistance. In support of the optimistic view, a recent population-based
study from our group showed an increase in viral suppression and a
decreasing incidence of potential resistance.17 Finally, there are persons
who are unaware of their HIV infection; most of them have high viral loads
and are more likely to engage in high-risk behaviours than they would if
they were aware of being infected. The prevalence of these persons is
unknown, and thus the extent of the problem is difficult to estimate.
Hence, the following needs to be considered. First, controlled treatment
interruptions have been shown to do more harm than good in the individual,18
nor are they justifiable from a population perspective, because of the
increased risk of transmission during periods of interruption. Secondly,
initiating HAART at an earlier stage-possibly treating all patients-is an
intervention that may restrain the spread of the epidemic. Thirdly,
intensified testing will help reduce the prevalence of risk behaviours and
improve viral suppression on the population level.
Other research questions are pending: What is the long-term impact of HIV
and HAART on the risk of non-HIV diseases? How do antiretroviral drugs
interact with other drugs in older individuals? Can we tailor individual
regimens based on genetic markers for drug susceptibility and on individual
risks for adverse drug reactions? What are the social and economic
consequences of a growing population of HIV-infected persons? Some will
require intensive medical care and receive financial support from the state,
but many will contribute to the economy through work and tax payments.
Ultimately, how can we transfer the success in the Western world to
resource-poor settings, where poverty may force patients into antiretroviral
drug-sharing and treatment interruptions? A requisite, contributory step
forward will be the development of a preventive and/or therapeutic HIV
vaccine.19
References
1 Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeficiency virus
infection. HIV Outpatient Study Investigators. N Engl J Med (1998)
338:853-60.[Abstract/Free Full Text]
2 Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and
without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007)
146:87-95.[Abstract/Free Full Text]
3 Frank L. Epidemiology. The epidemiologist's dream: Denmark. Science (2003)
301:163.[Abstract/Free Full Text]
4 Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association
Cohort Study, I: all-cause mortality in patients with insulin-treated
diabetes mellitus. Diabet Med (1999) 16:459-65.[CrossRef][ISI][Medline]
5 Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients:
are we there yet? J Heart Lung Transplant (2007)
26:103-7.[CrossRef][ISI][Medline]
6 Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of
non-AIDS-defining malignancies in HIV. Curr Opin Oncol (2006)
18:469-78.[ISI][Medline]
7 Lewden C, Salmon D, Morlat P, et al. Causes of death among human
immunodeficiency virus (HIV)-infected adults in the era of potent
antiretroviral therapy: emerging role of hepatitis and cancers, persistent
role of AIDS. Int J Epidemiol (2005) 34:121-30.[Abstract/Free Full Text]
8 Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons
infected with the human immunodeficiency virus: the D:A:D study. Arch Intern
Med (2006) 166:1632-41.[Abstract/Free Full Text]
9 Monforte AD, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and
risk of fatal AIDS-defining and non-AIDS-defining malignancies: results from
the D:A:D study. In: Abstracts of the Fourteenth Conference on Retroviruses
and Opportunistic Infections, Los Angeles, CA, 2007. Alexandria, VA, USA:
Foundation for Retrovirology and Human Health. Abstract 84.
10 Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active
antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS.
Am J Epidemiol (2007) 165:1143-53.[Abstract/Free Full Text]
11 Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV:
prevalence, AIDS progression, response to highly active antiretroviral
therapy and increased mortality in the EuroSIDA cohort. AIDS (2005)
19:593-601.[ISI][Medline]
12 Hansen AB, Gerstoft J, Kronborg G, et al. Mortality in siblings of
patients coinfected with HIV and hepatitis C virus. J Infect Dis (2007)
195:230-5.[CrossRef][ISI][Medline]
13 Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol
consumption and heavy drinking among people with HIV in the United States:
results from the HIV Cost and Services Utilization Study. J Stud Alcohol
(2002) 63:179-86.[ISI][Medline]
14 Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart
disease in patients treated for human immunodeficiency virus infection
compared with the general population. Clin Infect Dis (2003)
37:292-8.[CrossRef][ISI][Medline]
15 Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and
HIV disease progression: a tangled web is woven. J Antimicrob Chemother
(2005) 55:413-6.[Abstract/Free Full Text]
16 Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for
HIV testing of adults, adolescents, and pregnant women in health-care
settings. MMWR Recomm Rep (2006) 55:1-17.[Medline]
17 Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected
individuals at risk of transmitting drug-resistant HIV in Denmark during
1997-2004. Antivir Ther (2006) 11:591-600.[ISI][Medline]
18 El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption
of antiretroviral treatment. N Engl J Med (2006) 355:2283-96.[Abstract/Free
Full Text]
19 Titti F, Cafaro A, Ferrantelli F, et al. Problems and emerging approaches
in HIV/AIDS vaccine development. Expert Opin Emerg Drugs (2007)
12:23-48.[CrossRef][Medline]
--
Gary Stein
ge.s...@verizon.net
***********************************************************
For AIDS/HIV+ resources, visit the s.s.a.h+ website at :
http://www.webcom.com/benny/ssah/ssah+.html
***********************************************************